Bank of New York Mellon’s Akcea Therapeutics Inc AKCA Stock Holding History

Bank of New York Mellon’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-70,588	Closed	-$1.28M	–	4301
2020 Q3	$1.28M	Buy	70,588 +619	+0.9%	+$8.78K	﹤0.01%	2966
2020 Q2	$958K	Buy	69,969 +11,524	+20%	+$178K	﹤0.01%	3142
2020 Q1	$836K	Buy	58,445 +607	+1%	+$9.96K	﹤0.01%	3096
2019 Q4	$980K	Buy	57,838 +2,091	+4%	+$38.9K	﹤0.01%	3254
2019 Q3	$858K	Sell	55,747 -2,056	-4%	-$43.8K	﹤0.01%	3256
2019 Q2	$1.35M	Sell	57,803 -3,615	-6%	-$89.3K	﹤0.01%	3031
2019 Q1	$1.74M	Buy	61,418 +325	+0.5%	+$9.47K	﹤0.01%	2844
2018 Q4	$1.84M	Buy	61,093 +7,635	+14%	+$214K	﹤0.01%	2763
2018 Q3	$1.87M	Sell	53,458 -3,100	-5%	-$93.8K	﹤0.01%	2874
2018 Q2	$1.34M	Sell	56,558 -8,426	-13%	-$201K	﹤0.01%	3084
2018 Q1	$1.67M	Buy	64,984 +948	+1%	+$20.4K	﹤0.01%	2914
2017 Q4	$1.11M	Buy	64,036 +12,968	+25%	+$254K	﹤0.01%	3184
2017 Q3	$1.41M	Buy	+51,068	New	+$945K	﹤0.01%	3021

Bank of New York Mellon's AKCA Position: Q4 2020 in Review

Bank of New York Mellon sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 70,588 shares — an estimated $1.28M sold.

Bank of New York Mellon first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $1.87M in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

Bank of New York Mellon reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
Bank of New York Mellon sold 70,588 Akcea Therapeutics Inc shares in Q4 2020, an estimated $1.28M.
Bank of New York Mellon first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
Bank of New York Mellon's Akcea Therapeutics Inc position peaked at $1.87M in Q3 2018.
0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Bank of New York Mellon's 13F filing for Q4 2020, filed 9 Feb 2021.